Filing Flows › Comparisons › MKC vs MED
McCormick vs Medifast: MKC and MED compared
McCormick is the larger company: $2.0B of revenue in its latest quarter (Q3 FY26) against $72.0M for Medifast (Q3 2026). McCormick is growing faster (+17% against -19% a year earlier). McCormick is more profitable, with an operating margin of 10.7% against -26.9%.
Where the money goes: MKC and MED
McCormick (MKC) · Q3 FY26
McCormick, Q3 FY26: revenue $2.0B (+17% year over year), operating margin 10.7%, net earnings $97.6M, operating cash flow $168M. The chart follows the revenue to costs, profit and cash.
Medifast (MED) · Q3 2026
Medifast, Q3 2026: revenue $72.0M (-19% year over year), operating margin -26.9%, net loss $17.5M, operating cash flow $3.3M. The chart follows the revenue to costs, profit and cash.
| McCormick (MKC) | Medifast (MED) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q3 2026 |
| Revenue | $2.0B | $72.0M |
| Revenue growth, Y/Y | +17% | -19% |
| Gross margin | 39.3% | — |
| Operating margin | 10.7% | -26.9% |
| Net earnings | $97.6M | −$17.5M |
| Net margin | 4.8% | -24.3% |
| Operating cash flow | $168M | $3.3M |
| Free cash flow | $112M | $2.9M |
| Market value | $13.0B | — |
| P/E | 8.7× | — |
| Analysts’ mean target | $54.45 | — |
Questions
Which is bigger, McCormick or Medifast?
McCormick is the larger company: $2.0B of revenue in its latest quarter (Q3 FY26) against $72.0M for Medifast (Q3 2026).
Is McCormick or Medifast growing faster?
McCormick is growing faster (+17% against -19% a year earlier).
Which is more profitable, McCormick or Medifast?
McCormick is more profitable, with an operating margin of 10.7% against -26.9%.
More: McCormick earnings · how McCormick makes money · Medifast earnings · how Medifast makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 1, 2026; 10-Q filed Oct 26, 2026). Fiscal quarters can end on different dates. Not investment advice.